Annual report
4570.TEDINET S100R9RY
Period2022-04-01 → 2023-03-31
Filed2023-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 133
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥795m | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥648m | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥603m | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥577m | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥781m | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥58m | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | −¥122m | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | −¥150m | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥243m | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | −¥311m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥679m | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥156m | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥281m | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | −¥250m | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥290m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥259m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥319m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥668m | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥167m | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥290m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | −¥259m | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.4bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.7bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥1.8bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥2.4bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥3.0bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥356m | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥337m | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥1.6bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥1.9bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥2.1bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥614m | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥508m | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥562m | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥449m | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥552m | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥974m | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥1.5bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥26m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥93m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥194m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥609m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥244m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | ¥30m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥156m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥17m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥11m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥593m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥991,000 | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥144m | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥216m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥81m | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥126m | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-31.1 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-27.78 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-34.23 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-76 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-19.82 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥115.81 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥146.92 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥174.7 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥208.97 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥245.47 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 75.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 80.2% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 88.5% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.0% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.7% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Employees | 60 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 63 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 65 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 65 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 61 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥791m | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥604m | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥532m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥500m | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥631m | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥72m | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | −¥103m | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥66m | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥70m | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | −¥197m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥503m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | −¥160m | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥622m | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥116m | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | −¥631m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | −¥124m | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | −¥219m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥547m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥179m | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥2.0bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.4bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥2.9bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥306m | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥279m | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥1.1bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥1.8bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥2.1bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥2.1bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥556m | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥495m | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-67.74 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.27 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-23.52 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-62.24 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-21.21 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥116.86 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥184.61 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥197.88 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥221.41 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥244.88 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 78.1% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 86.1% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.5% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 73.4% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Shares issued | 9,314,590 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,314,590 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,314,590 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 9,314,590 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 8,724,590 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 59 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 62 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 58 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 56 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 52 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 35
| Segment | Item | Period | Value |
|---|---|---|---|
| Cosmeticsreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥4m |
| Cosmeticsreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥4m |
| Cosmeticsreportable segment | segment assets | at 2023-03-31 | ¥57m |
| Cosmeticsreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥13m |
| Gene Recombination Silkworm Developmentreportable segment | segment assets | at 2023-03-31 | ¥76m |
| Gene Recombination Silkworm Developmentreportable segment | segment profit | 2022-04-01 → 2023-03-31 | −¥80m |
| Immunity Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥791m |
| Immunity Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥791m |
| Immunity Relatedreportable segment | segment assets | at 2023-03-31 | ¥1.3bn |
| Immunity Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥152m |
| —segment total | employees | at 2023-03-31 | 60 pure |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥795m |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥795m |
| —segment total | segment assets | at 2023-03-31 | ¥1.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥58m |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | ¥560,000 |
| Cosmeticsreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥13m |
| Cosmeticsreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥13m |
| Cosmeticsreportable segment | segment assets | at 2022-03-31 | ¥93m |
| Cosmeticsreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥13m |
| Gene Recombination Silkworm Developmentreportable segment | segment assets | at 2022-03-31 | ¥453m |
| Gene Recombination Silkworm Developmentreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥95m |
| Immunity Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥637m |
| Immunity Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥634m |
| Immunity Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3m |
| Immunity Relatedreportable segment | segment assets | at 2022-03-31 | ¥1.2bn |
| Immunity Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | −¥15m |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥651m |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥648m |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥3m |
| —segment total | segment assets | at 2022-03-31 | ¥1.7bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | −¥123m |
| —segment total | employees | at 2023-03-31 | 59 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,261
| Item | Context | Value | Unit |
|---|---|---|---|
| Salaries and allowances sga | Prior1YearDuration_NonConsolidatedMember | 62132000 | JPY |
| Salaries and allowances sga | CurrentYearDuration_NonConsolidatedMember | 59140000 | JPY |
| Compensations sga | Prior1YearDuration_NonConsolidatedMember | 33554000 | JPY |
| Compensations sga | CurrentYearDuration_NonConsolidatedMember | 34804000 | JPY |
| Supplies expenses sga | Prior1YearDuration_NonConsolidatedMember | 1173000 | JPY |
| Supplies expenses sga | CurrentYearDuration_NonConsolidatedMember | 3166000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 187946000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 179656000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2023-06-30 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第41期（自 2022年４月１日 至 2023年３月31日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社免疫生物研究所 | |
| Company name in english cover page | FilingDateInstant | Immuno-Biological Laboratories Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 清藤 勉 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)群馬県藤岡市中字東田1091番地１ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)0274-22-2889（代表） | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)群馬県藤岡市中字東田1091番地１ | |
| Telephone number nearest place of contact cover page | FilingDateInstant | Original text (Japanese)0274-22-2889（代表） | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)常務取締役業務執行責任者兼事業グループ管理本部長 中川 正人 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00986 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45700 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社免疫生物研究所 | |
| Filer name in english | FilingDateInstant | Immuno-Biological Laboratories Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Current period end date | FilingDateInstant | 2023-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2021-04-01 | |
| Comparative period end date | FilingDateInstant | 2022-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2022-03-31 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |